Author | A. Bonnie Gillis


Novel Therapy First to Extend Survival in Advanced Melanoma

June 06, 2010


The results of a randomized phase III study showed that when ipilimumab (also known as MDX-010) was administered with or without the gp100 peptide vaccine, it extended survival by 34% compared with the gp100 peptide vaccine alone in patients with previously treated advanced melanoma.